IGF-1 HumanExplore study findings
What a placebo-controlled Rett syndrome trial found about mecasermin
2 numbered sourcesSource years 2018, 2026
Peptides are short amino-acid chains held together by peptide bonds. Some longer amino-acid chains influence how cells grow and communicate. Human insulin-like growth factor 1 (IGF-1) is a 70-residue hormone, and mecasermin is its recombinant pharmaceutical form. An older trial tested whether that medicine improved symptoms in children with Rett syndrome, a different question from treating growth failure. [1, 2]
No recent primary trial of mecasermin for this specific question was identified. In the older study, 30 girls with classic Rett syndrome were randomly assigned to receive either mecasermin or placebo in the first study period and switched to the other condition in the second. An interval separated the periods. The trial was double-blind, so participants, caregivers and the research team were masked to assignment. The investigators assessed several behavioral and clinical measures and examined exploratory recordings of breathing, heart function and brain activity. [1]
The trial did not find a statistically clear benefit across its principal comparisons. Some participants had deviations from the planned treatment exposure, which complicated interpretation. The investigators also reported adverse events during the study. In a crossover design, each participant can provide a comparison under both conditions. The interpretation still depends on the completeness of those observations and on whether changes from the first period could affect the second. [1]
The study shows why a proposed role for a signaling molecule in the nervous system is a rationale for testing, while measurable symptom change remains a separate question. The approved U.S. label for mecasermin covers defined pediatric growth disorders. Rett syndrome was the condition investigated in this trial and does not appear in those approved indications. The study's outcome applies to the tested medicine and does not establish how other compounds in the IGF-1 pathway would perform. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
